Dynamic MapReport
World News   USA   California   Bay Area   Business   Bio Tech   San Francisco (45)
San Francisco, Bio Tech Timeline Tuesday, May 8 Bookmark and Share     Author
Search Bay Area News Atlas:
Amgen to Buy Onyx for $10.4 Billion to Gain Cancer Drug  Amgen Inc. agreed to buy Onyx Pharmaceuticals Inc. in a $10.4 billion to give Amgen access to a rapidly expanding cancer-drug market Solazyme CEO resigns Solazyme's solid IPO  Startup that makes algae-based biofuel, raised nearly $200 million; the stock finished on the Nasdaq at $20.71 with a 15% gain Stock of InterMune soaring S.F. approves biodiesel plant Panel doesn't back Avastin for cancer Avastin delays ovarian cancer Bayer, Nektar moving into Mission Bay FDA Approves Actemra Arthritis Drug Medivation to develop cancer drug Taker found for Mission Bay office space   A growing South Bay biotech company Nektar Therapeutics Inc. will take over office space recently abandoned by drug giant Pfizer FDA clears drug for kidney cancer  Food and Drug Administration approved its cancer treatment Avastin for a new use, marking the sixth approval for the blockbuster drug Axe falls at Genentech  Anxiety rippled through Genentech as Roche began to cut rank-and-file jobs as it folds the South SF biotech firm into its global operations Pfizer drops planned research center  New York drug giant has pulled the plug on plans to open a biotech research center near UCSF's Mission Bay Campus Drug Raptiva pulled from market  The unit of drugmaker Roch is pulling the psoriasis treatment Raptiva off the U.S. market because of links to an often fatal brain infection Roche to take over Genentech for $47B
World News (13) World Bio Tech (28) USA (336) California (187) Bay Area (13) Bay Area Bio Tech (139) Business (1699) Bio Tech (139) San Francisco (45)
Avastin (14) Tech Conference (6) Pfizer (5) Herceptin (3) Lucentis (2)
   San Francisco (19)    North San Mateo County (39)    Daly City    SF Downtown (5)    SF City Hall    Giants    South SF (40)    Bay Bridge (3)    Brisbane (10)    Genentech (48)

2016 (1) 2015 (1) 2014 (3) 2013 (4) 2011 (3) 2010 (5) 2009 (11) 2008 (8) 2007 (1) 2006 (2) 2005 (1) 2004 (3) 2003 (2)
San Francisco on Wikipedia San Francisco on Web
Roche (16)   Eastern Span Bridge Construction   San Francisco Bridge Construction   Bay Area Construction (195)   Bay Area Merger and Acquisition (252)

Merger and Acquisition Main Event: Work movi...
San Francisco, Bio Tech on Google Map

B. 2016-09-13 Developer knew about Millennium Tower sinking before selling units Millennium Tower, South of Market
2. 2015-03-31 Horizon Pharma to buy Brisbane’s Hyperion Therapeutics Brisbane
3. 2014-08-24 Roche buys Brisbane drugmaker InterMune for $8.3 billion Brisbane
4. 2014-07-02 Genentech to buy Seragon Pharmaceuticals Genentech
F. 2014-03-17 Biotech deal could mean $350 million for Five Prime Therapeutics South SF
G. 2013-10-14 Genentech invests $285 million in biotech in state Genentech
H. 2013-09-02 New Bay Bridge ready for on-time opening Eastern Span
2013-09-01 Work moving quickly on new Bay Bridge span Eastern Span
9. 2013-08-27 Amgen to Buy Onyx for $10.4 Billion to Gain Cancer Drug South SF

Genentech to buy Seragon Pharmaceuticals Biotech deal could mean $350 million for Five Prime Therapeutics Genentech invests $285 million in biotech in state New Bay Bridge ready for on-time opening Work moving quickly on new Bay Bridge span
Developer knew about Millennium Tower sinking before selling units Horizon Pharma to buy Brisbane’s Hyperion Therapeutics  Horizon Pharma agreed to buy Brisbane’s Hyperion Therapeutics for $1.1 billion to gain drugs to treat rare metabolic diseases Roche buys Brisbane drugmaker InterMune for $8.3 billion

year 2016 Top ^

Sep.13   South of Market

year 2015 Top ^

Mar.31   Brisbane

year 2014 Top ^

Aug.24   Brisbane
  Swiss pharmaceutical giant is expanding its respiratory disease treatments by acquiring InterMune at $74 per share in an all-cash transaction
Jul.2   Genentech
Mar.17   South SF

year 2013 Top ^

Oct.14   Genentech
Sep.2   Eastern Span
Sep.1   Eastern Span
  Round-the-clock work to open the new eastern span is proceeding smoothly and transportation officials are putting the finishing touches on a ceremony
Aug.27   South SF

year 2011 Top ^

Dec.28   South SF
May.27   South SF
Apr.27   Brisbane

year 2010 Top ^

Dec.2   SF City Hall
Jul.20   Genentech
Jul.2   Genentech
May.17   San Francisco
Jan.9   Genentech

year 2009 Top ^

Oct.27   San Francisco
Oct.3   San Francisco
Aug.2   Genentech
Jul.9   Genentech
Jul.6   San Francisco
Apr.8   Genentech
Mar.12   Genentech
  Swiss giant agreed to buy the 44% of biotech pioneer that it doesn't already own, ending a long corporate struggle
 The $95-per-share deal brings Roche all of the sales of cancer drugs as well as its promising research pipeline. The deal offers $95 per share for the 44 percent of Genentech that Roche Holding AG doesn't already own
Mar.9   Genentech Roche-Genentech deal called close  Roche is reportedly willing to pay Genentech $95 a share, up from the $93, in what would be a $46.7 billion deal Mar.6   Genentech Roche raises bid for Genentech  Swiss drugmaker increased its offer to $93 per share. Genentech shares shot up to $90.05, gaining $8.41 or 10 percent Feb.9   Genentech Roche launches $86.50-a-share bid  Swiss drugmaker officially launched its $42 billion hostile offer for the 44% of Genentech Inc. it doesn't already own Jan.30   Genentech Roche revives takeover bid of Genentech  Swiss drugmaker, frustrated by stalled negotiations, plans a hostile takeover at a lower price than the $89 per share rejected in August

year 2008 Top ^

Nov.18   Genentech Avastin linked to higher risk of clots  A team of university researchers: Blockbuster cancer drug is linked to a significantly increased risk of blood clots in the veins Aug.27   South SF Cell Genesys Drug Trial Halts Aug.13   Genentech Genentech rejects Roche's $43.7b bid Aug.6   San Francisco Pfizer moving biotech research unit to S.F.
  The world's largest drugmaker will move the headquarters of its new biotech research unit to Mission Bay, next door to UCSF's new campus
Jul.21   Genentech Roche Offers $44B For Remaining Shares Apr.30   Genentech Bad news on cancer drug Rituxan Apr.24   Genentech Court slashes $200 million from judgment Feb.22   Genentech FDA Clears Avastin for Breast Cancer
  A Genentech drug received federal approval, a surprise decision

year 2007 Top ^

Dec.5   Genentech FDA Panel Rejects Avastin, stock drops

year 2006 Top ^

Jul.31   Genentech Tony Blair Visits Genentech Headquarters
Feb.13   Genentech Cancer Drug Trials Scaled Back

year 2005 Top ^

Jul.11   Genentech Profits Soar 73% in 2Q

year 2004 Top ^

Nov.4   Brisbane VaxGen gets contract for anthrax vaccine
  The government is purchasing 75 million doses of a new generation vaccine under an $877.5 million Jun.8   SF Downtown 150 protesters held at biotech conference
  About 200 demonstrators failed to shut down the annual Biotechnology Industry Organization convention
Jun.6   SF Downtown Biotech conference opens
  18,000 biotechnology scientists, executives and government officials were welcomed with a mayor and jeering protesters

year 2003 Top ^

May.19   Genentech Encouraging results with cancer drug
  Avastin extended the lives of some of the colon cancer patients. Company's stock soaring nearly 45% Feb.23   Brisbane AIDS vaccine developed by VaxGen
  An experimental vaccine does not protect most people, but showed promise in protecting blacks and Asians

Add a favorite (file a bookmark) to San Francisco, Bio Tech Timeline

Please send feedback to: support@mapreport.com

Advertise on San Francisco, Bio Tech Page

To sell or purchase a home in the San Francisco complete this form